Stock Analysis on Net
Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

$24.99

Operating Profit Margin
since 2012

Microsoft Excel

Paying user area

Try for free

AbbVie Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

AbbVie Inc., operating profit margin, long-term trends, calculation

Microsoft Excel
Operating profit margin = 100 × Operating earnings1 ÷ Net revenues1
Dec 31, 2024 = 100 × ÷
Dec 31, 2023 = 100 × ÷
Dec 31, 2022 = 100 × ÷
Dec 31, 2021 = 100 × ÷
Dec 31, 2020 = 100 × ÷
Dec 31, 2019 = 100 × ÷
Dec 31, 2018 = 100 × ÷
Dec 31, 2017 = 100 × ÷
Dec 31, 2016 = 100 × ÷
Dec 31, 2015 = 100 × ÷
Dec 31, 2014 = 100 × ÷
Dec 31, 2013 = 100 × ÷
Dec 31, 2012 = 100 × ÷

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).

1 US$ in millions

The financial data reveals significant variations and several notable trends in key performance indicators over the analyzed period.

Operating Earnings
Operating earnings demonstrated considerable fluctuation through the years. After an initial decline from 2012 to 2014, there was a strong recovery peaking in 2019 with a value above 12 billion US dollars. Following this peak, earnings experienced a decline into 2024, with a pronounced reduction in 2024 relative to prior years. The volatility suggests periods of operational challenges and recovery.
Net Revenues
Net revenues exhibited a consistent upward trajectory across the entire period under review, increasing from approximately 18 billion US dollars in 2012 to over 56 billion US dollars by 2024. This sustained growth indicates successful revenue expansion, possibly through increased sales volume, pricing adjustments, or portfolio growth strategies.
Operating Profit Margin
The operating profit margin varied substantially, reflecting changes in profitability relative to revenues. Margins declined sharply in 2014 before rebounding in subsequent years, reaching the highest levels near 39% in 2019. However, after 2019, the margin showed a downward trend, ending at a lower level in 2024 compared to early years. This pattern aligns with fluctuations in operating earnings and may indicate varying cost structures or investment impacts.

Overall, while net revenues consistently increased, operating earnings and profit margins were more volatile. This suggests that while top-line growth was strong, profitability faced pressures from operational factors or cost management challenges during certain years.

Comparison to Competitors

AbbVie Inc., operating profit margin, long-term trends, comparison to competitors

Microsoft Excel
AbbVie Inc. Amgen Inc. Danaher Corp. Gilead Sciences Inc. Regeneron Pharmaceuticals Inc. Thermo Fisher Scientific Inc. Vertex Pharmaceuticals Inc.
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Dec 31, 2015
Dec 31, 2014
Dec 31, 2013
Dec 31, 2012

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).